| acute heart failure | levosimendan | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| REVIVE II, 2013 | levosimendan vs placebo | | | | | REVIVE-I, 2003 | levosimendan vs placebo | | | | | RUSSLAN, 2002 | levosimendan vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| REVIVE II, 2013 | Intravenous Levosimendan (n=299) vs. placebo (n=301) | patients with decompensated chronic heart failure | double blind Parallel groups Sample size: 299/301 Primary endpoint: worsening heart failure FU duration: 5 days | | REVIVE-I, 2003 | levosimendan 0.1–0.2 mg/kg/min (n=-9) vs. placebo (n=-9) | patienst with HF andsymptoms at rest | Parallel groups Sample size: -9/-9 Primary endpoint: composite clinical FU duration: | | RUSSLAN, 2002 | Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h (n=-9) vs. placebo (n=-9) | patients with left ventricular failure complicating acute myocardial infarction | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: hypotension or myocardial ischaemia FU duration: 14 days |
|
| acute heart failure | levosimendan | not classified | versus active treatment No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SURVIVE, 2007 | levosimendan vs dobutamine | | | all cause death (6M+) 0.91 [0.74; 1.12] Short term death (30d) 0.85 [0.63; 1.15] | | CASINO | levosimendan vs dobutamine | | | | | LIDO, 2002 | levosimendan vs dobutamine | | | |
| Trial | Treatments | Patients | Method |
|---|
| SURVIVE, 2007 | Intravenous levosimendan (n=664) vs. intravenous dobutamine (n=663) | patients hospitalized with acute decompensated heart failure who required inotropic support | double-blind Parallel groups Sample size: 664/663 Primary endpoint: all cause mortality FU duration: 180 days | | CASINO | Levosimendan 16 mg/kg þ 0.2 mg/kg/min (n=-9) vs. Dobutamine (10 mg/kg/min) and placebo (n=-9) | patients withdecompensatedlow-output HF | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | LIDO, 2002 | Levosimendan (n=-9) vs. Dobutamine (n=-9) | patients with low-output heart failure | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: haemodynamic improvement FU duration: 24h |
|
